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Abstract
Background: Extracts of Tripterygium wilfordii Hook F (TWHF), a traditional Chinese herb, have
been reported to show efficacy in patients with rheumatoid arthritis (RA). Since RA is not only
characterized by inflammation but also by synovial proliferation in the joints, we examined whether
triptolide (a constituent of TWHF) could influence the proliferation of rheumatoid synovial
fibroblasts (RSF) by induction of apoptosis.
Results: RSF were obtained from RA patients during surgery and were treated with triptolide
under various conditions. The viability and proliferation of RSF were measured by the 4-[3-(4-
iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate (WST-1) assay and by 5-
bromo-2'-deoxyuridine incorporation, respectively. Apoptosis was identified by detection of DNA
fragmentation using an enzyme-linked immunosorbent assay and terminal deoxynucleotidyl
transferase-mediated dUTP nick-end labelling (TUNEL). The role of caspases in apoptosis of RSF
was analyzed by measuring caspase-3 activity. Activation of the peroxisome proliferator-activated
receptor (PPAR) γ was assessed by a luciferase reporter gene assay using RSF transfected with a
plasmid containing the peroxisome proliferator response element. Triptolide decreased viability,
inhibited proliferation, and induced apoptosis of RSF in a concentration-dependent manner at very
low (nM) concentrations. Caspase-3 activity was increased by treatment with triptolide and was
suppressed by caspase inhibitors. Although PPARγ activation was induced by 15-deoxy-∆12,14-
prostaglandin J2, triptolide did not induce it under the same experimental conditions. An extract of
TWHF also induced DNA fragmentation in RSF.
Conclusion: The mechanism of action remains to be studied; however, triptolide may possibly
have a disease-modifying effect in patients with RA.
Background
Extracts of Tripterygium wilfordii Hook F (TWHF) have
been reported to show efficacy in patients with a variety of
inflammatory and autoimmune diseases, including rheu-
matoid arthritis (RA) [1-3]. Previous studies have shown
that several TWHF extracts can exert immunosuppressive
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and anti-inflammatory effects in vivo. A chloroform
extract of TWHF suppresses type II collagen-induced
arthritis in mice [4], while carrageenan-induced inflam-
mation in rats is suppressed by the ethyl acetate extract of
TWHF [5].
The mechanism of action of these TWHF extracts has been
investigated in vitro. It has been shown that a multi-glyco-
side chloroform/methanol extract of TWHF (GTW) signif-
icantly inhibits proliferation and interleukin (IL)-2
productions by activated T cells [6]. GTW also inhibits the
production of IL-1, IL-6, IL-8, tumor necrosis factor
(TNF)-α, and prostaglandin (PG) E2 by human peripheral
blood monocytes, as well as IgG, IL-2, and IL-4 produc-
tion by human peripheral blood lymphocytes [7]. Like-
wise, a chloroform/methanol extract known as T2,
significantly inhibits the release of PGE2 and IL-2 from
human peripheral blood mononuclear cells [8]. We have
previously reported that the anti-rheumatic effect of GTW
or TWHF might be partly mediated through inhibition of
PGE2 production by human synovial cells due to down-
regulation of IL-1β-induced cyclooxygenase (COX)-2
mRNA expressions, possibly via the inhibition of nuclear
factor (NF)-κB activity [9]. TWHF also inhibits T cell pro-
liferation via the induction of apoptosis [6].
Triptolide is an active compound that was identified in
extracts of TWHF [10,11], and its actions have been
reported to be as follows: inhibition of IL-2 production by
mouse T cell hybridomas [12], human peripheral blood
lymphocytes, and Jurkat cells through nuclear inhibition
of transcriptional activation of NF-κB [13]; inhibition of
vascular endothelial growth factor expression [14]; sup-
pression of NF-κB in T lymphocytes [15]; inhibition of IL-
8 expression in human bronchial epithelial cells [13];
reduction of PGE2 production in human monocytes and
RA synovial fibroblasts (RSF) [16]; and inhibition of pro-
matrix metalloproteinase-1 and -3 mRNA expression [17].
Taken together, these results suggest that triptolide may be
an active compound from TWHF extracts with immuno-
suppressive and anti-inflammatory effects. However, it
has not been clarified whether triptolide exerts a disease-
modifying effect on the pathophysiology of RA. Since
induction of apoptosis in synovial cells may be a possible
therapeutic strategy for RA, we examined whether trip-
tolide could induce the apoptosis of RSF.
Results
Effect of triptolide on RSF viability
To determine whether triptolide had an influence on the
viability of RSF, we first evaluated the effects of various
anti-rheumatic drugs on cell viability using the 4-[3-(4-
iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-ben-
zene disulfonate (WST-1) assay. Triptolide caused a
marked decrease of cell viability in a concentration-
dependent manner (Figure 1), while bucillamine, D-pen-
icillamine, methotrexate, sulphasalazine, and sodium
aurothiomalate did not decrease viability at a concentra-
tion of 10 µM. The mean (± S.D.) value of 50% inhibitory
concentration (IC50) of 6 independent experiments was
74.3 ± 9.5 nM.
Effect of triptolide on RSF proliferation
Since triptolide reduced the viability of RSF, we also exam-
ined its effect on cell proliferation (DNA synthesis) by
measuring the incorporation of 5-bromo-2'-deoxyuridine
(BrdU) (Figure 2) using an enzyme-linked immunosorb-
ent assay (ELISA). Triptolide caused marked suppression
of cell proliferation in a concentration-dependent manner
and it was almost completely inhibited at 100 nM. In con-
trast, the other drugs that were tested, such as bucillamine,
D-penicillamine, and methotrexate, did not suppress the
proliferation of RSF. The mean (± S.D.) value of IC50 of 7
independent experiments was 20.4 ± 2.4 nM.
Induction of apoptosis in RSF by triptolide
To determine whether the decrease of viability and sup-
pression of proliferation when RSF were treated with trip-
tolide was related to apoptosis, we examined the effect of
triptolide on DNA fragmentation (a hallmark of
Effects of triptolide and anti-rheumatic drugs on the viability  of rheumatoid synovial fibroblasts (RSF). Figure 1
Effects of triptolide and anti-rheumatic drugs on the 
viability of rheumatoid synovial fibroblasts (RSF). 
Cells were incubated with triptolide (closed diamond), buci-
llamine (closed triangle), methotrexate (closed circle), D-
penicillamine (open triangle), sodium aurothiomalate (open 
diamond), or sulphasalazine (open circle) for 24 h. Then via-
bility was measured by the WST-1 assay and calculated as a 
percentage of the control value (untreated cells). Data are 
the mean ± S.D. for triplicate cultures and representative 
results from 6 independent experiments are shown.
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apoptosis). An ELISA that specifically detected cytoplas-
mic histone-associated DNA fragments, mononucleo-
somes and oligonucleosomes, was used to quantitatively
analyze DNA fragments. As shown in Figure 3, triptolide
induced DNA fragmentation in cultured RSF, while buci-
llamine, D-penicillamine, and methotrexate did not affect
cellular DNA. The mean (± S.D.) value of triptolide con-
centration at a half of maximum fold induction of 5 inde-
pendent experiments was 35.9 ± 16.3 nM.
Cell morphology was observed with a light microscope
after treatment of RSF with triptolide (Figure 4). When
synovial cells were incubated with triptolide (100 nM) for
24 h, distinctive morphological changes occurred, such as
cellular rounding, shrinkage, and membrane blebbing,
and the cells became separated from neighbouring cells
(panel b). The terminal deoxynucleotidyl transferase-
mediated dUTP nick-end labelling (TUNEL) assay was
used to confirm the apparent pro-apoptotic effect of trip-
tolide. As shown in panel d, TUNEL-positive cells were
observed after incubation with 100 nM triptolide for 24 h,
accounting for 66 % of the cultured RSF. These results sug-
gested that triptolide caused a decrease of RSF prolifera-
tion by the induction of apoptosis.
Effects of triptolide and anti-rheumatic drugs on the prolifer- ation of RSF. Figure 2
Effects of triptolide and anti-rheumatic drugs on the 
proliferation of RSF. Cells were incubated with triptolide 
(closed diamond), bucillamine (closed triangle), methotrexate 
(closed circle), or D-penicillamine (open triangle) for 24 h. 
Then cell proliferation was estimated from the incorporation 
of BrdU and calculated as a percentage of the control value 
(untreated cells). Data are the mean ± S.D. for triplicate cul-
tures and representative results from 7 independent experi-
ments are shown.
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Effects of triptolide and anti-rheumatic drugs on DNA frag- mentation of RSF. Figure 3
Effects of triptolide and anti-rheumatic drugs on 
DNA fragmentation of RSF. Cells were incubated with 
triptolide (closed diamond), bucillamine (closed triangle), 
methotrexate (closed circle), or D-penicillamine (open trian-
gle) for 24 h, after which fragmented DNA in the cytoplasm 
was measured by enzyme immunoassay and the fold induc-
tion of DNA fragmentation was calculated relative to the 
control value (untreated cells). Data are the mean ± S.D. for 
triplicate cultures and representative results from 5 inde-
pendent experiments are shown.
Morphological changes of RSF (a, b) and detection of apopto- sis by the TUNEL assay (c, d). Figure 4
Morphological changes of RSF (a, b) and detection of 
apoptosis by the TUNEL assay (c, d). Cells were incu-
bated for 24 h without (a, c) or with (b, d) triptolide at 100 
nM. Brown cells are apoptotic cells that show TUNEL stain-
ing, while blue cells are normal cells stained with methyl-
green. Original magnification × 200.












&
0
#

H
T
C
I
O
G
P
V
C
V
K
Q
P



H
Q
N
F

K
P
F
W
E
V
K
Q
P

   
%QPEGPVTCVKQP
µ/
c a
b dBMC Pharmacology 2004, 4 http://www.biomedcentral.com/1471-2210/4/2
Page 4 of 10
(page number not for citation purposes)
Effect of triptolide on caspase activity in RSF
Caspases are responsible for many of the biochemical and
morphological changes that occur during apoptosis, so we
investigated whether triptolide induced the activation of
caspase-3 in RSF. As shown in Figure 5, incubation of RSF
with 100 nM triptolide for 24 h induced the activation of
caspase-3, while activation was completely blocked by
incubation with the pan-caspase inhibitor Z-VAD-FMK.
We then examined effects of caspase inhibitors on trip-
tolide induced-apoptosis in RSF. Triptolide-induced DNA
fragmentation in RSF was suppressed by Z-DEVD-FMK, Z-
IETD-FMK, and Z-LEHD-FMK, inhibitors of caspases-3, -8
and -9, respectively, in concentration dependent manner
(Figure 6).
Effect of triptolide on PPARγ activation in RSF
To explore whether proliferator-activated receptor
(PPAR)γ activation was involved in the apoptotic effect of
triptolide, we performed a luciferase reporter gene assay
by co-transfection of RSF with a peroxisome proliferator
response element (PPRE)-driven luciferase reporter plas-
mid and a PPARγ expression plasmid (Figure 7). Incuba-
tion with 15-deoxy-∆12,14-prostaglandin J2 (15dPGJ2), a
PPARγ ligand, significantly induced PPRE-driven
luciferase activity in this system. In contrast, triptolide had
little influence on PPARγ activation despite causing the
apoptosis of RSF.
Induction of apoptosis in RSF by GTW
Since triptolide was regarded as a major active compound
of GTW, an extract of TWHF, we examined whether GTW
induced apoptosis in RSF. As show in Figure 8, GTW
induced DNA fragmentation in RSF at 10 to 30 µg/mL.
With GTW at 50 µg/mL, the cells had undergone
secondary (type 2) necrosis, which usually occurs after
apoptosis during in vitro experiments.
Discussion
The present study showed that triptolide, which has been
identified as a major active compound in TWHF extract,
induced the apoptosis of RSF. Triptolide as well as TWHF
extracts have been shown to inhibit cell growth by induc-
tion of apoptosis in several kinds of lymphocytes and can-
cer cell lines, as reviewed by Chen et al. [18]. However,
this is the first evidence that triptolide induces apoptosis
of RSF.
Extracts of TWHF (T2 and GTW) and triptolide have very
similar actions, such as suppressing the production of NF-
κB by T lymphocytes [15], IL-8 by human bronchial epi-
thelial cells [13], and PGE2 by human monocytes [16] and
RSF [9,16]. Triptolide has been reported to display both
immunosuppressive and anti-inflammatory effects
[13,16,19,20]. These findings suggest that it is a major
active compound of TWHF extracts.
RA is characterized by extensive inflammation and prolif-
eration of the synovium in various joints and synovial
hyperplasia leads to joint destruction. Proliferation of
synovial cells contributes to hyperplasia of the synovium
and to the formation of inflammatory pannus tissue,
which exhibits tumor-like proliferation and invades the
articular cartilage and surrounding tissues [21]. Nishioka
et al. [22] have suggested that the stimulation of
proliferation by TNF-α and induction of apoptosis by Fas
ligand play an important role in regulating the growth of
rheumatoid synovial tissue. Hyperplasia of invasive syno-
vial cells has been suggested to arise from an imbalance
between cell proliferation and apoptotic death [23].
Therefore, the identification of agents that induce apopto-
sis of RSF may be a key step toward the successful treat-
ment of RA [24]. Our finding that triptolide induces the
apoptosis of RSF may help to explain the anti-rheumatic
effect of TWHF extract in clinical studies [1]. Although we
found that triptolide could induce the apoptosis of RSF,
standard disease-modifying anti-rheumatic drugs like
methotrexate and sulphasalazine did not induce apopto-
sis. Low-dose methotrexate and sulphasalazine have been
reported to inhibit radiographic progression of joint
changes in patients with RA [25,26]. We found that
Effect of triptolide on caspase activity in RSF. Figure 5
Effect of triptolide on caspase activity in RSF. RSF 
were cultured without agents for 24 h, or were incubated 
with 100 nM triptolide or 100 nM triptolide plus 10 µM Z-
VAD-FMK, and then caspase activity was measured by the 
CaspACE™ assay system (Promega) as the absorbance at 
405 nm. Data are the mean ± S.D. for 3 independent experi-
ments. *, p < 0.01 versus untreated control cells and versus 
cells treated with triptolide plus Z-VAD-FMK. Significance 
was evaluated by Student's t-test with a Bonferroni's 
correction.
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triptolide and GTW could induce the apoptosis of RSF,
suggesting that triptolide might have a stronger effect than
conventional disease-modifying anti-rheumatic drugs.
Tao et al. [3] studied the efficacy and safety of TWHF
extract in patients with RA. They found that TWHF extract
improved the symptoms of RA according to American
College of Rheumatology criteria. In addition, it
decreased C-reactive protein, rheumatoid factor, and the
erythrocyte sedimentation rate, changes that were not
Effects of triptolide and caspase inhibitors on DNA fragmentation in RSF. Figure 6
Effects of triptolide and caspase inhibitors on DNA fragmentation in RSF. Cells were incubated with triptolide with/
without caspase inhibitors for 24 h, after which fragmented DNA in the cytoplasm was measured by enzyme immunoassay and 
the fold induction of DNA fragmentation was calculated relative to the control value (untreated cells). Data are the mean ± 
S.D. for triplicate cultures and representative results from 3 independent experiments are shown. *, p < 0.05 versus cells 
treated with triptolide alone. Significance was evaluated by Student's t-test with a Bonferroni's correction in each caspase inhib-
itor study.
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seen during treatment with non-steroidal anti-inflamma-
tory drugs.
Generally, apoptosis is the result of complex intracellular
proteolysis mediated by defined group of intracellular
proteases known as caspases. Apoptotic programs are
depending on whether the signal originates from inside or
outside of the cell [27]. The intrinsic pathway, initiator
caspase-9 is activated by the release of mitochondrial
components constituted of cytochrome c and ATP. The
extrinsic pathway known as death receptor stimulation
(Fas, TNF-related apoptosis inducing ligand; TRAIL, TNF
receptor-1) requires activation of caspase-8. Then apopto-
sis was accomplished via activation of caspase-3. In paral-
lel, caspase-8 can cleavage BID into truncated BID (tBID)
[28]. The tBID stimulates the release of cytochrome c from
mitochondria, leading to activation of caspase-9. There-
fore, receptor-mediated death signalling is also connected
to the mitochondrial apoptosis signalling pathway. In the
present study, activation of caspase-3 was increased when
cells were treated with triptolide. This triptolide-induced
activation of caspase-3 was suppressed by Z-VAD-FMK, a
pan-caspase inhibitor. Therefore, induction of apoptosis
by triptolide was dependent on the caspase-3 pathway.
Our results showed those inhibitors of not only caspase-
3, but also caspases-8 and -9 suppressed triptolide
induced-DNA fragmentation in RSF. Yang et al. [12]
reported that over expression of Bcl-2, which inhibit mito-
chondrial intrinsic pathway, suppressed triptolide-
induced degradation of poly ADP-ribose polymerase, a
caspase substrate, and apoptosis of T lymphocytes. In con-
trast, our data suggest that triptolide-induced apoptosis in
RSF was performed by both intrinsic and extrinsic
pathways.
There have been several reports suggesting the mechanism
of triptolide-induced apoptosis in cancer cell lines. Jiang
et al. [29] found that suppression of p53 expression by an
antisense oligonucleotide could prevent triptolide-
induced apoptosis, while over-expression of dominant
negative p53 abolished the inhibitory effect on NF-κB
activation in human gastric cancer cells. In contrast, it was
reported that triptolide has a broad spectrum of pro-apop-
totic activity against several kinds of cancer cells that
express wild-type or mutant forms of p53 [30]. Lee et al.
[31] suggested that NF-κB is an important factor for pro-
apoptotic action of triptolide on cancer cell lines.
Recently, Frese et al. [32] reported that TRAIL-induced
apoptosis in lung cancer cells was sensitized by triptolide
via activation of ERK2, a member of the mitogen-activated
protein kinase family. On the other hand, it was reported
Effect of triptolide on activation of PPARγ in RSF. Figure 7
Effect of triptolide on activation of PPARγ in RSF. 
Cells were co-transfected with a PPRE-driven luciferase 
reporter plasmid, a PPARγ expression plasmid, and an inter-
nal control plasmid. Then the transfected cells were treated 
with known PPARγ ligand or triptolide and luciferase activity 
was determined as described in Materials and Methods. Data 
are the mean ± S.D. for triplicate cultures and representative 
results from 3 independent experiments are shown. *, p < 
0.05 versus other groups. Significance was evaluated by Stu-
dent's t-test with a Bonferroni's correction.
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Effect of GTW on DNA fragmentation in RSF. Figure 8
Effect of GTW on DNA fragmentation in RSF. Cells 
were incubated with GTW for 24 hr, after which fragmented 
DNA in the cytoplasm was measured by enzyme immu-
noassay and the fold induction of DNA fragmentation was 
calculated relative to the control value (untreated cells). Data 
are the mean ± S.D. for triplicate cultures and representative 
results from 3 independent experiments are shown. *, p < 
0.01 versus untreated control cells. Significance was evalu-
ated by Student's t-test with a Bonferroni's correction.
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[33,34] that 15dPGJ2 and troglitazone, natural and syn-
thetic ligand of PPARγ, respectively, could induce RA syn-
oviocyte apoptosis in vitro. We previously found that
some nonsteroidal anti-inflammatory drugs induce the
apoptosis of RSF in a COX-2-independent, but PPARγ-
dependent, manner [34]. We also reported that celecoxib,
a selective COX-2 inhibitor, induce apoptosis and sup-
press the proliferation of RSF [35] without activation of
PPARγ. In the present study, however, triptolide did not
induce PPARγ activation. Intracellular mechanism of pro-
apoptotic action of triptolide except for PPARγ activation
in RSF is to be studied.
In this study, GTW induced apoptosis in RSF in concentra-
tion dependent manner. It was reported that triptolide
and tripdiolide were purified from aqueous extract of
TWHF [11]. Although we did not examine experiments
with tripdiolide, one of the major active compounds of
GTW might be triptolide. Furthermore, studies should be
conducted to clarify the mechanism of the pro-apoptotic
action of triptolide in RSF.
Conclusions
We demonstrated that triptolide, an active compound,
identified in a traditional Chinese herb, induced apopto-
sis of RSF. The mechanism of action remains to be stud-
ied; however, triptolide may possibly have a disease-
modifying effect in patients with RA.
Methods
Chemicals
RPMI-1640 medium, penicillin-streptomycin solution,
fetal bovine serum (FBS), and trypsin-EDTA were
obtained from Gibco BRL (Gaithersburg, MD, USA).
Triptolide was purchased from Biomol Research Labora-
tories, Inc. (Plymouth Meeting, PA, USA). 15dPGJ2 was
obtained from Cayman Chemical (Ann Arbor, MI, USA).
Bucillamine, D-penicillamine, and salazosulfapyridine
(sulphasalazine) were purchased from Sigma Chemical
Co. (St. Louis, MO, USA). Sodium aurothiomalate was
obtained from Shionogi & Co., Ltd. (Osaka, Japan). Z-
DEVD-FMK (a caspase-3 inhibitor), Z-IETD-FMK (a
caspase-8 inhibitor) and Z-LEHD-FMK (a caspase-9 inhib-
itor) were purchased from R&D Systems, Inc.
(Minneapolis, MN, USA). GTW powder was kindly pro-
vided by Taizhou Pharmaceutical Co. (Jiang Su, China).
All other chemicals were purchased from Wako Pure
Chemical Industries (Osaka, Japan).
Culture of human RSF
RSF were prepared from synovial tissues, as described pre-
viously [36]. The synovial tissues were obtained during
total knee replacement from RA patients who fulfilled the
revised American Rheumatism Association criteria [37].
Mean (± S.D.) age of 18 patients (14 female) with RA were
64.3 ± 5.8. The protocol for this study was approved by
the ethics committee of St. Marianna University and all
patients gave written consent to the use of their tissues for
this research. Synovial tissues were digested for 2 h with
0.2 % (w/v) bacterial collagenase (Immuno-Biological
Laboratories Co., Ltd., Gunma, Japan) and then the syno-
vial cells were suspended in RPMI-1640 medium with 10
% (v/v) FBS, 100 U/ml penicillin, and 100 µg/ml
streptomycin. The cells were incubated at 37°C in 5 %
CO2 for several days, after which nonadherent cells were
removed. The fibroblast-like adherent cells were used as
RSF within 2 passages. These adherent cells contained no
T cells (CD3+) or macrophage/monocytes (CD14+) on
two-colour immunofluorescence and flow cytometry. All
culture condition of RSF in RPMI-1640 medium contain-
ing 1 % (v/v) FBS under an atmosphere of 5 % CO2.
Preparation of drugs
Test drugs except GTW were dissolved in dimethyl sulfox-
ide (DMSO) as 1000 × stock solutions and then diluted
with RPMI-1640 medium containing 1 % (v/v) FBS for
cell culture experiments. GTW powder was dissolved in
ethanol, filtrated, and then stored at -20°C. Test drug
solutions were prepared freshly on the day of use. The
final concentration of DMSO or ethanol (just for GTW
study) for all treatments (including control cultures) was
0.1 % (v/v).
Cell viability assay
RSF (2 × 104 cells/well) were incubated in 96-well plastic
plates with test drugs in the condition described above.
After 24 h, cell viability was assessed by measuring
mitochondrial NADH-dependent dehydrogenase activity
with a Cell Counting Kit (Dojindo Molecular Technolo-
gies, Inc., Kumamoto, Japan) using a sulfonated tetrazo-
lium salt, 2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-
disulfophenyl)-2H-tetrazolium monosodium salt, (WST-
1) [38]. Each measurement was done in triplicate and the
results are presented as a percentage of the value for
untreated control cultures.
Cell proliferation assay
The proliferation of RSF was assessed from the incorpora-
tion of 5-bromo-2'-deoxyuridine (BrdU). Cells (1 × 104
cells/well) were incubated in 96-well plastic plates with
the test drugs in the condition described above. Then
BrdU (10 µM) was added to the medium and the cells
were incubated for another 18 h. Subsequently, the cells
were fixed and BrdU incorporation was determined with
a Cell Proliferation ELISA Kit (Roche Diagnostics GmbH,
Mannheim, Germany) according to the manufacturer's
instructions. Each measurement was done in triplicate
and the results are presented as a percentage of the value
for the untreated control culture.BMC Pharmacology 2004, 4 http://www.biomedcentral.com/1471-2210/4/2
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DNA fragmentation assay
DNA fragmentation was detected by ELISA and by TUNEL
assay. RSF were plated in 96-well plastic plates (2 × 104
cells/well) and cultured for 24 h. Then the cells were incu-
bated for a further 24 h with test drugs in the condition
described above. After incubation, DNA fragmentation
was investigated using a Cell Death Detection ELISAPLUS
kit (Roche Diagnostics GmbH) [39]. Each measurement
was done in triplicate and the results are presented as the
fold induction compared with untreated control cultures.
Terminal deoxynucleotidyl transferase-mediated dUTP 
nick end labelling assay
RSF (2.5 × 104 cells/well) were incubated in 8-well cham-
ber slides (Iwaki, Chiba, Japan) for 24 h with triptolide in
the condition described above. Then morphological
changes of the cells were observed under a microscope
(BX51, Olympus Optical Co., Ltd., Nagano, Japan), after
which the cells were fixed with 4 % (v/v) neutral buffered
formalin for 10 min at room temperature. Subsequently,
apoptotic synovial cells were identified by the TUNEL
assay using an Apoptosis in situ Detection Kit (Wako Pure
Chemical Industries) according to the manufacturer's
instructions. Sections were counterstained with methyl-
green (Wako Pure Chemical Industries) before
observation.
Caspase activity assay
RSF were incubated in tissue culture flask with or without
triptolide and/or Z-VAD-FMK (a pan-caspase inhibitor) in
the condition described above. After 24 h, caspase activity
in the cells was measured using the CaspACE™ assay sys-
tem (Promega, Madison, WI, USA) according to the man-
ufacturer's instructions. Cells were washed in ice-cold
phosphate-buffered saline (PBS, 9.57 mM, pH 7.35–7.65,
Takara Shuzo, Shiga, Japan), and resuspended in cell lysis
buffer. After the cells were lysed by freezing and thawing,
the lysates were centrifuged and the supernatant was used
as the cell extract. The protein content of the extracts was
determined by the BCA protein assay (Pierce, Rockford,
IL, USA) with bovine serum albumin (BSA) as the stand-
ard, and extracts were adjusted to a protein content of 1
mg/ml.
Luciferase reporter assay
A luciferase reporter plasmid, containing 4 copies of the
PPRE of the acyl-CoA oxidase gene promoter [40] at the
Nhe I restriction site in the firefly luciferase expression
vector PGV-P2 (Toyo Ink, Tokyo, Japan), was used to
measure PPARγ activation [34]. RSF (6 × 104 cells/well)
were seeded into 24-well culture plates in RPMI-1640
medium containing 10 % (v/v) FBS. After culture for 24 h
at 37°C under an atmosphere of 5 % CO2, the cells were
co-transfected with the reporter plasmid (0.1 µg/well),
with a PPARγ expression plasmid containing mouse
PPARγ 2 cDNA [41] at the Hind III and Xba I restriction
sites in the pRc/CMV expression vector (Invitrogen, Gron-
ingen, The Netherlands) (0.1 µg/well), and with an inter-
nal control plasmid (pRL-SV40; Promega) (0.01 µg/well)
using Effectene Transfection Reagent (12 µg/mL, Qiagen,
Hilden, Germany) according to the manufacturer's
instructions. After incubation for a further 24 h at 37°C
under an atmosphere of 5 % CO2, the transfection
mixture was replaced by RPMI-1640 medium containing
1% (v/v) FBS with or without one of the test drugs. After
additional incubation for 18 h in the condition described
above, luciferase activity was determined using the Dual-
Luciferase Reporter Assay System (Promega) and a TD-20/
20 luminometer (Turner Designs, Sunnyvale, CA, USA)
according to the manufacturer's instructions. Each meas-
urement was done in triplicate and firefly luciferase activ-
ity was normalized to Renilla luciferase activity.
Statistical analysis
Data are expressed as the mean ± S.D. Statistical analysis
was done using multiple Student's t-tests with a
Bonferroni's correction. A probability value of less than
0.05 was taken to indicate a significant difference.
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